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Abstract
Surgical resection followed by radiotherapy and temozolomide in newly diagnosed glioblastoma can prolong
survival, but it is not curative. For patients with disease progression after frontline therapy, there is no standard of
care, although further surgery, chemotherapy, and radiotherapy may be used. Antiangiogenic therapies may be
appropriate for treating glioblastomas because angiogenesis is critical to tumor growth. In a large, noncomparative
phase II trial, bevacizumab was evaluated alone and with irinotecan in patients with recurrent glioblastoma;
combination treatment was associated with an estimated 6-month progression-free survival (PFS) rate of 50.3%, a
median overall survival of 8.9 months, and a response rate of 37.8%. Single-agent bevacizumab also exceeded the
predetermined threshold of activity for salvage chemotherapy (6-month PFS rate, 15%), achieving a 6-month PFS
rate of 42.6% (p < 0.0001). On the basis of these results and those from another phase II trial, the US Food and
Drug Administration granted accelerated approval of single-agent bevacizumab for the treatment of glioblastoma
that has progressed following prior therapy. Potential antiangiogenic agents-such as cilengitide and XL184-also
show evidence of single-agent activity in recurrent glioblastoma. Moreover, the use of antiangiogenic agents with
radiation at disease progression may improve the therapeutic ratio of single-modality approaches. Overall, these
agents appear to be well tolerated, with adverse event profiles similar to those reported in studies of other solid
tumors. Further research is needed to determine the role of antiangiogenic therapy in frontline treatment and to
identify the optimal schedule and partnering agents for use in combination therapy.
Introduction
The incidence rates of primary malignant brain and cen-
tral nervous system (CNS) cancers have increased over
the last 3 decades [1], reaching an estimated rate of 6.8
new cases per 100,000 persons in the United States [2].
Glioblastoma is the most common primary malignant
brain tumor and accounts for the majority of diagnoses.
On the basis of data collected between 1995 and 2006,
glioblastoma has been associated with a particularly
poor prognosis, with survival rates at 1 and 5 years
equaling 33.7% and 4.5%, respectively [3]. The current
standard of care for patients with newly diagnosed
glioblastoma is surgical resection followed by fractionated
external beam radiotherapy and systemic temozolomide
[4], as supported by data from a randomized phase III
trial, which demonstrated a significant improvement with
the addition of temozolomide to radiotherapy in median
overall survival (OS) from 12.1 months to 14.6 months
[5]. Although this treatment can prolong survival, it is
not curative. The vast majority of patients with glioblas-
toma experience recurrent disease, with a median time to
recurrence of 7 months [6].
Currently, there is no standard treatment for patients
with recurrent glioblastoma, although additional surgery,
chemotherapy, and radiotherapy are used. An analysis of
data from phase II clinical trials showed the limitations
of conventional chemotherapy regimens, which were
associated with a 6-month progression-free survival
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patients with recurrent disease [7]. More recent trials of
single-agent temozolomide or irinotecan, also known as
CPT-11, have demonstrated only slight increases in
6-month PFS, with the highest rate being 26% [8-10].
Recommended chemotherapeutic options for recurrent
glioblastoma include temozolomide, nitrosourea, cyclo-
phosphamide, platinum-based combination regimens,
and procarbazine, lomustine, and vincristine combina-
tion therapy [4]. Moreover, in May 2009, the US Food
and Drug Administration (FDA) granted accelerated
approval of single-agent bevacizumab for the treatment
of patients with glioblastoma that has progressed follow-
ing prior therapy [11]. The National Comprehensive
Cancer Network (NCCN) guidelines have subsequently
been amended to include a recommendation for the use
of bevacizumab, with or without chemotherapy (i.e., iri-
notecan, bischloroethylnitrosourea, or temozolomide),
for progressive glioblastoma [4]. Enrollment in a clinical
trial is considered standard practice at recurrence.
Bevacizumab is a humanized monoclonal antibody
that targets vascular endothelial growth factor (VEGF),
an important mediator of angiogenesis that is essential
for the tumorigenesis of glioblastoma. Antiangiogenic
therapies may arrest tumor growth by mediating the
regression of existing tumor vasculature and preventing
regrowth over time [12,13]. As a result, bevacizumab
and other antiangiogenic agents, including cediranib
(AZD2171), aflibercept (VEGF Trap), XL184 and cilen-
gitide (EMD 121974), are being evaluated for use in
recurrent and newly diagnosed glioblastoma (Figure 1).
This article reviews the available data from clinical trials
of antiangiogenic agents in glioblastoma, either as single
agents or in combination with chemotherapy and/or
radiotherapy.
Rationale For Using Antiangiogenic Therapies In
The Treatment Of Glioblastoma
Glioblastomas are associated with a high degree of
microvascular proliferation, and the extent of prolifera-
tion correlates with an increased risk of recurrence and
poor survival [14]. VEGF-A (also known as “VEGF”)i s
one of the most well-studied and potent vascular perme-
ability factors, with an established role in pathologic
angiogenesis [15]. Studies evaluating VEGF levels in
plasma and tumor fluid from patients have shown that
glioblastomas express relatively high levels of VEGF
[16,17], and mean intracavitary levels of VEGF are signifi-
cantly increased in patients with recurrent glioblastoma
relative to those with nonrecurrent disease [16]. More-
over, there is a direct correlation between VEGF overex-
pression and poor prognosis in this tumor histology [18].
Preclinical studies have provided evidence that the
inhibition of the VEGF ligand can modulate tumor
vasculature. In a study using neuroblastoma xenografts,
Dickson and colleagues demonstrated that treatment
with bevacizumab led to reductions in microvessel den-
sity and improvement in the function of intratumoral
blood vessels (Figure 2), facilitating the penetration of
subsequent chemotherapy [19]. In another glioblastoma
model, bevacizumab suppressed both the proangiogenic
effects of stem cell-like glioma cells (SCLGCs) in vitro
and the growth of SCLGC-derived glioblastoma xeno-
grafts in vivo [20]. Data also suggest an association
between other proangiogenic factors, such as the angio-
poietins, neuropilin-1, and delta-like ligands, and the
survival and/or proliferation of tumor cells [21-23]. Col-
lectively, these results highlight the importance of VEGF
and the related signal transduction pathways as thera-
peutic targets in glioblastoma and provide the rationale
for evaluating antiangiogenic agents in clinical trials.
Clinical Experience With Antiangiogenic Agents In
Glioblastoma
Antiangiogenic agents with chemotherapy for recurrent
glioblastoma
In the initial investigation in patients with recurrent
glioblastoma, bevacizumab was evaluated in combination
with concomitant irinotecan [24]. This combination was
supported by the activity of bevacizumab with irinote-
can-containing regimens in patients with metastatic col-
orectal cancer [25], by the relative lack of single-agent
activity of thalidomide in recurrent glioblastoma [26],
and by preclinical evidence, suggesting that antiangio-
genic agents enhance intratumoral chemotherapy deliv-
ery [19,27]. Additionally, antiangiogenic agents may
supplement the effect of chemotherapy by inhibiting the
activity of a population of SCLGCs that is not as well
differentiated (i.e., chemotherapy-resistant) [20]. The
existence of these cells may partially explain tumor
resistance to radiotherapy and chemotherapy, and could
contribute to the recurrence of glioblastoma.
Use of bevacizumab with chemotherapy
Data from prospective and retrospective studies indicate
that regimens combining bevacizumab and chemother-
apy produce superior outcomes relative to those with
conventional chemotherapy in patients with recurrent
glioblastoma [7]. In the first prospectively designed,
phase II trial, patients with recurrent glioblastoma
received bevacizumab plus irinotecan in one of two
treatment cohorts: the first cohort (n = 23) received
bevacizumab 10 mg/kg plus irinotecan q2w in a 6-week
cycle, and a second cohort (n = 12) received bevacizu-
mab 15 mg/kg q3w with irinotecan on days 1, 8, 22, and
29 of a 6-week cycle [28,29]. In both cohorts, irinotecan
was administered at 340 mg/m
2 to 350 mg/m
2 in
patients on enzyme-inducing antiepileptic drugs
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2 in those not receiving
EIAEDs. The 6-month PFS rate among all 35 patients
was 46%, the 6-month OS rate was 77%, and the median
OS was 42 weeks [29]. In addition, the overall response
rate (ORR) was high (57%). Recently, the 4-year survival
rate in this trial was reported to be 11% [30] (Table 1).
The toxicity of the combination of bevacizumab and iri-
notecan was considered to be significant but acceptable,
considering the poor prognosis of the population [29].
Eleven (31%) of the 35 patients discontinued treatment
because of adverse events, which included thromboem-
bolic complications (n = 4), grade 2 proteinuria (n = 2),
and grade 2 fatigue (n = 4); one patient experienced a
CNS hemorrhage.
More recently, Friedman and colleagues investigated the
use of bevacizumab with or without irinotecan in a rando-
mized noncomparative phase II trial of 167 patients with
recurrent glioblastoma-the BRAIN study [31,32]. In this
trial, patients were randomized to bevacizumab 10 mg/kg
q2w alone (n = 85) or in combination with irinotecan (n =
82). For patients treated with bevacizumab and irinotecan,
the estimated 6-month PFS rate was 50.3%, the median
OS was 8.9 months, and the ORR was 37.8% at the 6-
month follow-up. At 27 months of follow-up, the 12-, 18-,
24-, and 30-month survival rates were 38%, 18%, 17%, and
16%, respectively. In the safety population for the combi-
nation arm (n = 79), the most common grade ≥ 3 adverse
events were convulsion (13.9%), neutropenia (8.9%), and
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Figure 1 Molecular targets of antiangiogenic agents in glioblastoma. Cilengitide is a cyclic peptide that binds to and inhibits the activities
of the alpha(v)beta(3) and alpha(v)beta(5) integrins. Bevacizumab is a humanized monoclonal immunoglobulin G1 antibody that binds to and
inhibits VEGF-A. Aflibercept is a fusion protein that binds all isoforms of VEGF-A, as well as PlGF. Cediranib, sunitinib, vandetanib, XL184, and
CT-322 are multireceptor tyrosine kinase inhibitors. ABT-510 is a nonapeptide that targets the thrombospondin-1 receptor CD36. Abbreviations:
EGFR = epidermal growth factor receptor; PDGFR = platelet-derived growth factor receptor; PlGF = placental growth factor; VEGF-A = vascular
endothelial growth factor A; VEGFR = vascular endothelial growth factor receptor.
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nuation for 14 (17.7%) patients. Adverse events associated
with bevacizumab included grade ≥ 3 arterial thromboem-
bolism (2.5%), grade ≥ 3 wound-healing complications
(1.3%), grade ≥ 3 venous thromboembolism (10.1%), grade
3 gastrointestinal perforation (2.5%), serious reversible
posterior leukoencephalopathy syndrome (1.3%), and
intracranial hemorrhage (3.8%). In addition, there was one
death associated with convulsion in patients treated with
bevacizumab and irinotecan.
Data from additional phase II studies, retrospective
analyses, and case series of consecutive patients have
provided further support for the activity of bevacizumab
with chemotherapy in patients with recurrent glioblas-
toma [33-39]. In these studies, 6-month PFS rates have
ranged from 6.7% to 64% in patients with recurrent glio-
blastoma. In general, bevacizumab was shown to be well
tolerated in both prospective and retrospective studies,
and no unexpected treatment-related adverse events
were reported (Table 2). Reported events were typical of
those associated with bevacizumab in the treatment of
other tumor types. For example, hypertension and pro-
teinuria have been reported as the most frequently
occurring treatment-related adverse events in studies of
bevacizumab therapy in other solid tumors [11,25,40].
The incidence of thromboembolic complications in
patients with recurrent glioblastoma receiving bevacizu-
mab plus chemotherapy ranged from 11.4% to 12.7% in
the two prospective studies [28,29,32]. The relation of
bevacizumab to these events, however, is unclear
because patients with malignant gliomas are already at
an increased risk for symptomatic venous thromboem-
bolism. In a retrospective study of 9489 cases of malig-
nant glioma, the 2-year cumulative incidence of venous
thromboembolism was relatively high at 7.5% (n = 715
cases) [41]. Furthermore, a diagnosis of glioblastoma
was identified as a specific risk factor for venous throm-
boembolism (hazard ratio [HR] = 1.7; 95% confidence
interval [CI], 1.4-2.1). Overall, the safety profile of beva-
cizumab with chemotherapy has been within acceptable
limits, without any indications of additive toxicities.
Other antiangiogenic therapies used with chemotherapy
for recurrent glioblastoma
Clinical trials have also evaluated the safety and efficacy of
other antiangiogenics, specifically thalidomide and vatala-
nib, in combination with chemotherapy agents. In phase II
trials of patients with recurrent glioblastoma, thalidomide-
containing regimens produced 6-month PFS rates between
23% and 27% and objective response rates between 6% and
24% [42-45]. Although the findings of two of these studies
suggested that combination therapy was more active than
either thalidomide or the chemotherapy partner alone, the
benefit-to-risk ratio of thalidomide-containing therapy has
not been clearly established, particularly when considering
that certain combinations are complicated by significant
adverse events (e.g., neutropenia and thromboembolism).
A phase I/II trial of vatalanib plus temozolomide (n = 37)
or lomustine (n = 23) provided evidence of activity in
patients with recurrent glioblastoma-patients receiving
vatalanib and temozolomide had a median time to pro-
gression of 16.1 weeks and a partial response rate of 9%
Day 0
tumor
skin
Day 1 Day 3 Day 7
Figure 2 Intravital microscopy images showing the effect of a single dose of bevacizumab on the intratumoral vascular phenotype of
an orthotopic neuroblastoma (NB-1691 xenograft) model. Images were obtained on days 0, 1, 3, and 7. Original magnification was ×40.
Vasculature of normal skin is also shown [19]. Reprinted with permission from Dickson PV, Hamner JB, Sims TL, et al. Bevacizumab-induced
transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered
chemotherapy. Clin Cancer Res 2007;13:3942-3950; Figure 2.
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been discontinued from further investigation in patients
with glioblastoma.
Single-agent activity of antiangiogenic therapies in
recurrent glioblastoma
As data from trials of antiangiogenic agents and che-
motherapy in the recurrent setting began to emerge,
questions arose about the relative contribution of concomi-
tant cytotoxic therapy in these regimens. Single-agent anti-
angiogenic strategies were effective in other solid tumors,
including renal cell carcinoma and ovarian cancer
[40,47,48]. Thus, clinical trials were initiated to investigate
whether single-agent approaches were appropriate in
patients with recurrent glioblastoma, anticipating that they
might provide antitumor control while minimizing toxicity.
Table 1 Efficacy outcomes with antiangiogenic agents in recurrent glioblastoma
Reference, (n
a) Treatment regimen Response rate
(%)
b
Progression-free survival
CR PR SD Median At 6 months
(%)
Bevacizumab
Vredenburgh [28], (n = 23 of 32)
d BV + irinotecan 4 57 35 20 weeks 30
Vredenburgh [29], (N = 35) BV + irinotecan 57 N/A 24 weeks 46
Narayana [33], (n = 37 of 61)
e BV + irinotecan or carboplatin 13 60 21 5 months N/A
Friedman [31], Cloughesy [32], (N
= 167)
BV alone (n = 85)
BV + irinotecan (n = 82)
28
38
N/A
N/A
4.2 months
5.6 months
43
50
Reardon [38], (n = 27 of 59)
d BV + etoposide 4 19 70 18 weeks 44
Kreisl [49], (N = 48) BV ® BV + irinotecan 71 (Levin
criteria); 35
(MacDonald
criteria)
N/A 16 weeks 29
Gutin [92], (n = 20 of 25)
d BV + hypofractionated stereotactic irradiation 50 N/A 7.3 months 65
Aflibercept
De Groot [53], (n = 32 of 48)
d Aflibercept alone 0 30 52 N/A N/A
Cediranib
Batchelor [112], (N = 31) Cediranib alone 57
(volumetric
criteria); 27
(MacDonald
criteria)
N/A 117 days 26
Cilengitide
Reardon [50] (N = 81) Cilengitide alone (2000 mg/d [n = 40] or 500 mg/d
[n = 41])
0 9 N/A 2000 mg/d, 8.1
weeks
c
500 mg/d, 7.9 weeks
c
2000 mg/d, 15
500 mg/d, 10
CT-322
Schiff [113], (n = 51) CT-322 alone (n = 33)
CT-322 + irinotecan (n = 18)
1 (3)
0
1 (3)
0
N/A
N/A
N/A
N/A
23
48
XL184
Wen [54], (n = 105) XL184 175 mg qd
XL 184 125 mg qd
AAT-naive (n
= 34), 21
AAT-
pretreated
(n = 12), 8
AAT-naive (n
= 37), 30
AAT-
pretreated
(n = 22), 0
N/A
AAT-naive, 16 weeks
AAT-naive, 16 weeks
AAT-pretreated, 7.9
weeks
AAT-naive, 10
AAT-naive, 25
AAT-
pretreated, 0
Abbreviations: AAT = antiangiogenic therapy; BV = bevacizumab; CR = complete response; N/A = not available; PR = partial response; RT = radiotherapy; SD =
stable disease.
aNumber of patients with glioblastoma, where available.
bIn evaluable patients.
cTime to progression.
dEfficacy outcomes are reported for patients with glioblastoma only.
eEfficacy outcomes are reported for all patients.
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Page 5 of 15Table 2 Safety profile of antiangiogenic agents for recurrent glioblastoma
Reference, (n
a) Treatment
regimen
Patients
discontinuing
because of an
adverse event,
n (%)
Select grade 3 or 4
adverse events,
n (%)
b
Intracranial
hemorrhage
(any grade),
n (%)
Thromboembolic
events
(any grade),
n (%)
Treatment-
related
deaths,
n (%)
Bevacizumab-containing regimens
Vredenburgh [28],
(n = 23 of 32)
c
BV + irinotecan 9 (28.1) N/A 0 4 (12.5) 2 (6.3)
Vredenburgh [29],
(N = 35)
BV + irinotecan 11 (31.4) N/A 1 (2.9) 4 (11.4) N/A
Narayana [33],
(n = 37 of 61)
c
BV + irinotecan or
carboplatin
16 (26.2) Bone marrow toxicity, 6 (9.8) 6 (9.8) 6 (9.8) 0
Friedman [31],
Cloughesy [32],
(N = 167)
BV alone (n = 84)
BV + irinotecan (n
= 79)
4 (4.8)
14 (17.7)
All, 43 (51.2)
Hypertension, 9 (10.7)
Wound-healing complications, 2 (2.4)
Proteinuria, 1 (1.2)
All, 56 (70.9)
Hypertension, 3 (3.8)
Wound-healing complications, 1 (1.3)
Proteinuria, 3 (3.8)
GI perforation, 2 (2.5)
3 (3.6)
3 (3.8)
ATE, 4 (4.8)
VTE, 3 (3.6)
ATE, 3 (3.8)
VTE, 9 (11.4)
2 (2.4)
1 (1.3)
Reardon [38],
(n = 27 of 59)
c
BV + etoposide 7 (11.9) Neutropenia, 14 (23.7)
Infection, 5 (8.5)
Hypertension, 2 (3.4)
CNS
hemorrhage, 2
(3.4)
7 (11.9) 1 (1.7)
Kreisl [49],
(N = 48)
BV ® BV +
irinotecan
6 (12.5) Hypertension, 2 (4.2)
Hypophosphatemia, 2 (4.2)
Bowel perforation, 1 (2.1)
0 6 (12.5) N/A
Gutin [92],
(n = 20 of 25)
c
BV +
hypofractionated
stereotactic
irradiation
3 (12) Lymphopenia, 9 (36)
Hyponatremia, 6 (24)
Bowel perforation, 1 (4)
Wound-healing complication, 1 (4%)
GI bleeding, 1 (4%)
1 (4) N/A N/A
Aflibercept
De Groot [53],
(n = 32 of 48)
c
Aflibercept alone 12 (25) CNS ischemia, 1 (2.1)
Systemic hemorrhage, 1 (2.1)
N/A N/A N/A
Cediranib
Batchelor [112],
(N = 31)
Cediranib alone 2 (6.5) Fatigue, 6 (19.4)
ALT, 5 (16.1)
Hypertension, 4 (12.9)
N/A 1 (3.2) 0
Cilengitide
Reardon [50], Fink
[51],
(N = 81)
Cilengitide alone
(2000 mg/d [n =
40] or 500 mg/d
[n = 41])
N/A Convulsion, 2 (2.5)
Lymphopenia, 7 (8.6)
Neutropenia, 1 (1.2)
1 (1.2) N/A 5 (6.2)
CT-322
Schiff [113],
(n = 51)
CT-322 ±
irinotecan
13 (25.5) Neutropenia, 4 (7.8)
Hypertension, 3 (5.9)
CNS
hemorrhage, 1
(2.0)
N/A 1 (2.0)
XL184
Wen [54],
(n = 153)
XL184 (175 mg
qd [n = 46] or
125 mg qd [n =
107])
18 (11.8) Fatigue, 31 (20.3)
Hypertension, 8 (5.2)
GI perforation, 3 (2.0)
Wound-healing complications, 2 (1.3)
3 (2.0; grade
3/4)
17 (11.1) N/A
Abbreviations: ALT = alanine transaminase; ATE = arterial thromboembolic event; BV = bevacizumab; CNS = central nervous system; GI = gastrointestinal; N/A =
not available; VTE = venous thromboembolic event.
aNumber of patients with glioblastoma, where available.
bIntracranial hemorrhage and thromboembolic events are reported separately.
cSafety outcomes are reported for all patients.
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The approval of single-agent bevacizumab treatment for
patients with recurrent glioblastoma was based on an
improvement in objective response rates in two phase II
studies [31,49]. In a study by Kreisl and colleagues, 48
patients with heavily pretreated glioblastoma (median of
two prior chemotherapy regimens) received bevacizu-
mab 10 mg/kg q2w until disease progression [49].
At progression, patients received bevacizumab plus iri-
notecan. During the monotherapy phase of the study,
the median PFS was 16 weeks (95% CI, 12-26 weeks),
the 6-month PFS rate was 29% (95% CI, 18%-48%), and
the ORR was 35% (one complete response). When
response assessment criteria were based on both World
Health Organization (WHO) ra d i o g r a p h i cc r i t e r i aa n d
on stable or decreasing corticosteroid use, the objective
response rate was 19.6% (95% CI, 10.9%-31.3%) [11].
The median OS was 31 weeks (95% CI, 21-54 weeks),
and the 6-month OS was 57% (95% CI, 44%-75%). Sin-
gle-agent bevacizumab was well tolerated; the most fre-
quently observed treatment-related adverse events were
grade 3 or 4 thromboembolic events (12.5%), grade 2 or
3 hypertension (12.5%), grade 2 or 3 hypophosphatemia
(6%), and grade 2 or 3 thrombocytopenia (6%). Of the
six patients (12.5%) who experienced a thromboembolic
event, three had pulmonary emboli and one had a cere-
bral vascular event. Thromboembolic events in five
patients and one instance of bowel perforation in
another led to the removal of six patients (12.5%) from
the study. No instances of intracranial hemorrhage were
reported.
The safety and efficacy of single-agent bevacizumab
was further substantiated by a large, randomized, non-
comparative phase II study (BRAIN) in which patients
with glioblastoma in first or second relapse were rando-
mized to bevacizumab alone or in combination with iri-
notecan [31,32]. Outcomes for patients treated with
both bevacizumab and irinotecan in the BRAIN study
have been described earlier. Patients who received beva-
cizumab monotherapy (n = 85) had a 6-month PFS rate
of 42.6% (95% CI, 29.6%-55.5%), an ORR of 28.2% (one
complete response), and a median OS of 9.3 months.
Responses, categorized both by WHO radiographic cri-
teria and by stable or decreasing corticosteroid use,
were seen in 25.9% (95% CI, 17.0%-36.1%) of patients
[11]. As in the combination arm, the 6-month PFS rate
in the monotherapy arm surpassed the 15% rate
assumed for salvage chemotherapy and single-agent iri-
notecan (p < 0.0001). The 12-, 18-, 24-, and 30-month
OS rates were 38%, 24%, 16%, and 11%, respectively. No
unexpected adverse events were reported, and there was
a low incidence of intracranial hemorrhage. Forty-three
(51.2%) patients eligible for the safety analysis (n = 84)
had grade ≥ 3 adverse events, including hypertension
(10.7%), venous thromboembolism (3.6%), wound-heal-
ing complications (2.4%), and arterial thromboembolism
(3.6%). Three (3.4%) patients who received single-agent
bevacizumab experienced intracranial hemorrhage; all of
t h e s ee v e n t sw e r eg r a d e≤2. Two patients died as a
result of an adverse event (neutropenia infection and
pulmonary embolism, respectively), and four patients
(4.8%) discontinued bevacizumab treatment because of
adverse events.
Although the randomized design of the trial was
intended only to prevent bias in treatment assignment
and not to compare outcomes in the two treatment
groups, it is notable that bevacizumab monotherapy was
associated with a lower rate of grade ≥ 3 adverse events
(51.2% vs 70.9%) than the combination of bevacizumab
and irinotecan [32]. Furthermore, in the two studies
evaluating bevacizumab monotherapy [31,49], the rate of
treatment discontinuation owing to adverse events was
relatively low (4.8% and 12.5%, respectively) compared
with discontinuation rates in the bevacizumab-plus-iri-
notecan arms of the Friedman and Vredenburgh studies
(17.7% and 31%, respectively) [29,31]. This suggests that
the rate of certain adverse events, such as infection, may
be reduced or even eliminated by the omission of
chemotherapy.
Single-agent data with other antiangiogenic agents
A number of other antiangiogenic therapies have been
studied or are being studied as single-agent therapy in
patients with recurrent glioblastoma, including cilengi-
tide, aflibercept, XL184, cediranib, sunitinib, and CT-
322 (see Tables 1 and 2). Long-term follow-up results
with the integrin inhibitor cilengitide have recently been
reported from a phase II trial in 81 patients with recur-
rent glioblastoma, in which cilengitide 500 mg (n = 41)
or 2000 mg (n = 40) was given twice weekly [50,51].
Median OS was 9.9 months in the 2000-mg arm com-
pared with 6.5 months in the 500-mg arm. OS rates
were consistently greater with the 2000-mg dose of
cilengitide (37%, 23%, 15%, and 10% at 12, 24, 36, and
48 months, respectively) compared with the 500-mg
dose (22%, 12%, 5%, and 2%, at 12, 24, 36, and 48
months, respectively) (HR = 0.635). Cilengitide was well
tolerated, with no significant reproducible toxicities in
the dose groups. For the 15 patients who received cilen-
gitide for more than 6 months, treatment-related
adverse events tended to occur within 6 months of
receiving the first dose of cilengitide; the most common
treatment-related adverse event was fatigue (n = 3), and
the most common grade 3 or 4 serious adverse event
was convulsion (n = 2). Only two patients reported ser-
ious adverse events from 6 months up to 4.5 years from
the first cilengitide dose (headache and memory impair-
ment). The investigators con c l u d e dt h a tc i l e n g i t i d e
monotherapy was well tolerated and feasible for >4
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consistently greater with the 2000-mg dose.
Aflibercept is a recombinantly produced fusion protein
that binds both VEGF and placental growth factor and
has been shown to suppress the growth of glioblastoma
xenografts in murine models [52]. In NABTC 0601, an
ongoing phase II study, patients with temozolomide-
resistant glioblastoma or anaplastic glioma at first
relapse receive aflibercept 4 mg/kg q2w [53]. Prelimin-
ary efficacy data in 27 patients with glioblastoma
revealed an ORR of 30%. Aflibercept showed moderate
tolerability-the rate of treatment discontinuation among
all 48 enrolled patients was 25%. Eighteen treatment-
related, grade 3 adverse events were reported. Mature
data will provide a better indication of the activity of
single-agent aflibercept in the recurrent setting.
Recently, interim results from a phase II study of
XL184, an oral inhibitor of multiple receptor tyrosine
kinases that includes VEGF receptor 2, in previously
treated progressive glioblastoma have been reported
[54]. In the cohort treated with XL184 175 mg (n =
46), the ORRs were 8% (1/12) and 21% (7/34) in
patients with and without previous exposure to anti-
angiogenic treatment, respectively. While none of the
22 patients previously treated with antiangiogenic
therapy responded to XL184 125 mg, the ORR in
patients with antiangiogenic-naive disease was 30%
(11/37) with the 125-mg dose. The median PFS in
both antiangiogenic-naive cohorts was 16 weeks. In
total, 61% (46/76) of patients on corticosteroids at
baseline had a reduction in corticosteroid dose of at
least 50%. Common grade 3 or 4 adverse events
among all 153 evaluable patients included fatigue
(20%), transaminase elevation (12%), and thromboem-
bolic events (10%). The investigators concluded that
XL184 demonstrates encouraging clinical activity in
patients with progressive glioblastoma and that the
125-mg dose of XL184 demonstrates improved toler-
ability compared with the 175-mg dose.
Continued use of antiangiogenic agents after progression
In the event of progression following treatment with an
antiangiogenic agent, patients with glioblastoma have
very few therapeutic options. For example, in a prospec-
t i v es t u d yb yK r e i s la n dc o l l e a g u e s ,ac o h o r to f1 9
patients was subsequently treated with bevacizumab
plus irinotecan after progression on bevacizumab mono-
therapy [49]. None of these patients responded to ther-
apy, and the median PFS was 30 days. In another
prospective phase II study of patients with recurrent
malignant gliomas treated with daily temozolomide, it
was found that patients with prior exposure to bevacizu-
mab fared worse than patients without bevacizumab
exposure (6-month PFS rate of 14% vs 36%, p = 0.12;
median OS of 4 vs 18 months, p = 0.005) [55]. Retro-
spective reviews of patients with glioblastoma treated
either with a bevacizumab-containing regimen or beva-
cizumab alone have also reported that these patients
have limited response to a second treatment, regardless
of whether it contains bevacizumab [36,56-59]. One
hypothesis for the lack of response after antiangiogenic
treatment is that an alteration of the tumor phenotype
results in a highly infiltrative compartment that is angio-
genic-independent. Further studies are warranted to
identify new therapeutic targets and novel agents that
could treat patients who have relapsed following antian-
giogenic therapy.
One of the concerns with the administration of anti-
angiogenic agents is the apparent potential for infiltra-
tive or invasive tumor growth upon disease progression
[33,35,36,60-62]. Recent reports, however, indicate that
antiangiogenic treatments may not significantly alter
patterns of relapse in glioblastoma. For example, in a
study of distant spread in 44 matched pairs of patients
with recurrent glioblastoma treated with or without bev-
acizumab-containing regimens, distant recurrences were
later observed in 22% (10/44) of bevacizumab-treated
patients compared with 18% (8/44) of non-bevacizu-
mab-treated patients on T1-weighted magnetic reso-
nance imaging (MRI) scans, and in 25% (11/44) of
bevacizumab-treated patients compared with 18% (8/44)
of non-bevacizumab-treated patients on fluid attenua-
tion inversion recovery (FLAIR) MRI sequences (p >
0.05). This proportion of distant recurrences was in line
with previous reports, without significant differences
between bevacizumab and non-bevacizumab-containing
treatments [63]. Moreover, a subanalysis of the BRAIN
study, in which patient MRI scans were compared at
baseline (prior to bevacizumab treatment) and at the
time of progression, showed that the majority of patients
(55/67 in the bevacizumab-alone group) had no shift in
the pattern of progression. A shift from local to diffuse
disease was seen in 16% (11/67) of patients in the beva-
cizumab-alone group [64]. Other investigators have like-
wise concluded on the basis of retrospective analyses of
radiographic patterns of relapse that the majority of dis-
ease patterns with glioblastoma are local at diagnosis
and remain so after recurrence and treatment with beva-
cizumab, and that the rate of nonlocal disease (diffuse,
distant, or multifocal) does not appear to increase with
the use of antiangiogenic agents [65-67]. Reports have
also differed regarding the impact of the pattern of
radiographic recurrence on survival outcomes
[36,58,64,67]. In cases in which an infiltrative phenotype
is observed at diagnosis, it is possible that antiangiogenic
therapy in combination with another agent that targets
tumor invasion, such as dasatinib [68], may be an effec-
tive therapeutic strategy.
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Increased understanding of molecular mechanisms in
the tumorigenesis of glioblastomas has led to the evalua-
tion of targeted agents as potential radiosensitizers
[69,70]. Preclinical models have shown that VEGF is
upregulated in response to radiation, and these eleva-
tions may contribute to the protection of tumor blood
vessels from radiation-mediated cytotoxicity [70,71]. The
administration of antiangiogenic agents with radiother-
apy may counteract VEGF-mediated radioresistance,
thereby sensitizing tumors and associated vasculature to
the ionizing effects of radiation (Figure 3) [69,70,72]. As
an underlying mechanism, the ability of antiangiogenic
agents to lower tumor interstitial fluid pressure and
improve vascular function and tumor oxygenation may
promote enhanced responsiveness to radiotherapy
[73,74]. Preclinical studies have also demonstrated that
antiangiogenic agents uniquely target the radioresistant
and highly tumorigenic cancer stem cell niche [20,75].
Finally, the success of initial clinical investigations of
bevacizumab with chemoradiation in patients with solid
tumors also supports the possible synergies of combined
modality therapy [76,77].
Efficacy of antiangiogenic agents and chemoradiation
The efficacy and safety of bevacizumab with chemother-
apy and radiotherapy have been assessed in clinical stu-
dies for the treatment of both recurrent and newly
diagnosed glioblastoma [78,79]. In the frontline setting,
the use of bevacizumab plus radiotherapy and temozolo-
mide has been described in two reports. In a phase II
pilot study, 10 patients with glioblastoma underwent
surgery followed by radiotherapy (30 fractions of 2 Gy
per fraction) with bevacizumab 10 mg/kg q2w plus con-
comitant temozolomide 75 mg/m
2 [78]. Temozolomide
therapy was continued until disease progression or for a
maximum of 24 cycles, while bevacizumab therapy con-
tinued every 2 weeks until progression. At the time of
reporting, the median PFS was >8.8 months, but it was
too early to establish the median OS. The most com-
monly occurring, possibly treatment-related adverse
events were fatigue, myelotoxicity, wound-healing com-
plications, and venous thromboembolic events. The only
unexpected toxicity was the development of presumed
radiation-induced optic neuropathy in one patient. The
study investigators noted, however, that the observed
toxicities were at an acceptable level to continue enroll-
ment toward a target of 70 patients.
In a subsequent feasibility study in a consecutive series
of patients, Narayana and colleagues reported outcomes
from 15 patients with high-grade glioma, including 12
patients with glioblastoma, who underwent surgery fol-
lowed by radiotherapy (59.4 Gy over 6.5 weeks) [79].
Bevacizumab 10 mg/kg was administered on days
14 and 28 along with concomitant temozolomide
75 mg/m
2 daily during radiotherapy. After the comple-
tion of radiotherapy, treatment with bevacizumab and
temozolomide continued for 12 cycles. At a median fol-
low-up of 12 months (range, 5-21 months), the PFS rate
was 59.3% and the OS rate was 86.7%. Nonhematologic
toxicities were reported in three patients (20%), and
grade 3 or 4 hematologic toxicities were reported in
another three patients (20%) [79]. No intracerebral
hemorrhage or treatment-related deaths occurred during
the study. Several ongoing clinical trials have also
recently reported interim data on the use of bevacizu-
mab with radiotherapy and either temozolomide or
irinotecan in patients with previously untreated glioblas-
toma [80-86]. In two of the trials with longer follow-up,
the addition of bevacizumab with or without irinotecan
to standard radiotherapy and temozolomide was shown
to provide significant benefit in PFS relative to historic
controls [80,82]. In one trial having a minimum follow-
up of 18 months, the regimen incorporating bevacizu-
mab and irinotecan was associated with a median PFS
that was approximately double that seen with standard
therapy in patients with newly diagnosed glioblastoma
(14 vs 6.9 months, respectively) [82]. In both trials, the
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Figure 3 Dose-dependent effect of radiation on VEGF protein
expression. VEGF protein levels in LLC-conditioned medium are
shown after radiation exposure. LLCs were plated in six-well plates
at 25% confluence, allowed to attach overnight, and then irradiated
with 0, 5, 10, or 20 Gy. Conditioned medium was collected every 24
hours and VEGF levels were normalized to cell number. Data are
presented as mean plus standard error [70]. Abbreviations: LLC =
Lewis lung carcinoma; VEGF = vascular endothelial growth factor.
Reprinted with permission from Gorski DH, Beckett MA, Jaskowiak
NT, et al. Blockage of the vascular endothelial growth factor stress
response increases the antitumor effects of ionizing radiation.
Cancer Res 1999;59:3374-3378; Figure 1B.
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regimens was considered to be tolerable [80,82]. Large
phase III studies evaluating bevacizumab-containing
regimens in patients with newly diagnosed glioblastoma
have recently begun enrolling patients, including a glo-
bal-based study (AVAglio [NCT00943826]) [87] and a
US-based study (RTOG-0825 [NCT00884741], which is
sponsored by the Radiation Therapy Oncology Group).
Results from a phase I/II trial of cilengitide in combi-
nation with temozolomide and radiotherapy in patients
with newly diagnosed glioblastoma have also demon-
strated promising efficacy [88]. After tumor resection,
52 patients received standard radiotherapy (2 Gy × 30
fractions) and temozolomide 75 mg/m
2, with cilengitide
500 mg twice weekly started 1 week before chemoradia-
tion and given throughout the duration of chemotherapy
or until progression. The 6-and 12-month PFS rates
were 69% and 33%, respectively; the median PFS was 8.0
months. The 12- and 24-month OS rates were 68% and
35%, respectively, with a median OS of 16.1 months.
The authors reported that PFS and OS in patients with
O(6)-methylguanine-DNA methyltransferase (MGMT)
promoter methylation (13.4 and 23.3 months, respec-
tively) were longer than those in patients without
MGMT promoter methylation (3.4 and 13.1 months,
respectively). Seven patients (14%) discontinued treat-
ment for adverse events that were possibly treatment-
related. The regimen was found to be well tolerated,
with no additional toxicities [88].
Early phase studies have evaluated additional antian-
giogenic agents, such as vatalanib, vandetanib, and ABT-
510, in combination with temozolomide and radiother-
apy for the treatment of patients with newly diagnosed
glioblastoma [89-91]. These trials provide further evi-
dence for the feasibility of combining these treatment
modalities in the frontline setting.
Recent studies have also reported on the feasibility of
using bevacizumab with radiotherapy in patients with
recurrent malignant gliomas [92,93]. One of these stu-
dies reported outcomes in 25 patients (20 patients with
glioblastoma and five patients with anaplastic glioma)
who received bevacizumab 10 mg/kg q2w until tumor
progression, along with hypofractionated stereotactic
r a d i o t h e r a p y( 3 0G yt o t a la s6G y×5f r a c t i o n s )a f t e r
the first cycle of bevacizumab therapy [92]. In the glio-
blastoma cohort, the regimen was associated with a
6-month PFS rate of 65% (95% CI, 40%-82%) and a
median PFS of 7.3 months (95% CI, 4.4-8.9 months).
The median OS was 12.5 months (95% CI, 6.9-22.8
months), the 1-year survival was 54%, and the ORR was
50%. The overall toxicity of the regimen was comparable
to that in other clinical trials of bevacizumab in glioblas-
toma [28,29,31,78]. Three patients in the overall popula-
tion experienced a grade 4 adverse event-bowel
perforation, wound-healing complication, and gastroin-
testinal bleeding. Other nonhematologic and hematolo-
gic toxicities were transient. No significant adverse
events appeared to be attributable to the interaction of
bevacizumab with radiation, with the exception of a sin-
gle instance of wound dehiscence; radiation necrosis was
not observed in this previously irradiated population.
Overall, the high 6-month PFS rate and improved thera-
peutic ratio of this combination suggest that it should
be investigated in larger trials of patients with recurrent
disease and supports ongoing trials of bevacizumab with
radiochemotherapy in patients with newly diagnosed
glioma.
Other considerations with antiangiogenic therapies
The role of antiangiogenic therapy also requires further
evaluation of its potential use in glioblastoma-related
conditions. One example is pseudoprogression, which
may be visualized on brain scans in patients who have
received chemoradiotherapy and temozolomide, result-
ing from increased cerebral edema. In clinical studies,
both bevacizumab and cediranib have shown activity in
reducing the need for steroid therapy to treat tumor-
associated cerebral edema [31,94]. Therefore, these
agents may be useful in cases in which pseudoprogres-
sion is suspected, as well as in patients with large, inop-
erable glioblastomas who are dependent on steroid
therapy.
Antiangiogenic treatment has also been proposed for
the management of radiation necrosis, a process in which
endothelial cell dysfunction leads to tissue hypoxia and
necrosis, with the concomitant release of vasoactive com-
pounds [95]. In a small randomized double-blind study,
Levin and colleagues reported outcomes in 14 patients
who received either placebo or bevacizumab for radiogra-
phically-proven or biopsy-proven CNS necrosis. All of
the bevacizumab-treated patients (5/5 randomized
patients; 7/7 crossover patients), but none of the placebo-
treated patients (n = 7), showed improvement in neurolo-
gic symptoms or signs and had a reduction in the volume
of necrosis on T2-weighted FLAIR (average reduction of
59% in randomized patients) and T1-weighted gadoli-
nium-contrast MRI (average reduction of 63% in rando-
mized patients) [96]. Similar radiographic responses,
along with improved or stable clinical outcomes,
were also achieved with bevacizumab treatment in a ret-
rospective analysis of eight patients with documented
radiation necrosis [95], as well as a case series of six
patients with biopsy-proven radiation necrosis [97].
In addition to its role in the treatment of glioblastoma,
bevacizumab has also been evaluated in other high-
grade gliomas. Results from phase II studies and retro-
spective reviews of bevacizumab for the treatment of
anaplastic gliomas have been encouraging. In a phase II
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gliomas (anaplastic astrocytoma, anaplastic oligodendro-
glioma, and anaplastic oligoastrocytoma), Desjardins and
colleagues found the use of bevacizumab and irinotecan
to be active (6-month PFS = 55%; 6-month OS = 79%;
ORR = 61%) and to have acceptable toxicity, with infre-
quent significant adverse events [98]. In a more recent
study of 31 patients with recurrent anaplastic glioma,
single-agent bevacizumab was associated with a median
PFS of 3.7 months, a median OS of 12.4 months,
reduced steroid requirements (a 40% reduction, on aver-
age, in steroid dose), and improved neurologic symp-
toms [99]. The activity and safety of single-agent
bevacizumab have also been described in retrospective
studies of patients with recurrent alkylator-refractory
anaplastic oligodendroglioma and anaplastic astrocytoma
[100,101]. The NCCN guidelines now include the use of
bevacizumab with or without chemotherapy as a treat-
ment option for recurrent anaplastic gliomas [4].
Another consideration is the impact of antiangiogenic
agents on radiographic evaluations of treatment response
in malignant gliomas. Some investigators argue that it is
challenging to determine disease progression and tumor
response to antiangiogenic therapy because of the effect
of these agents on vascular permeability, which results in
diminished contrast enhancement on computed tomogra-
phy or MRI scans [102-104]. Because the current stan-
dard response criteria (MacDonald criteria) are based on
contrast enhancement MRI, there is some debate as to
whether these criteria are still adequate in the era of anti-
angiogenic agents. Proposals for new treatment response
assessment criteria have been presented by various
authors and also by the Response Assessment in Neuro-
Oncology Working Group, and include taking into
account T2/FLAIR (non-contrast enhancing) imaging,
favoring the use of Levin criteria, or changing the criter-
ion of response by cross-sectional area of enhancement
measurement (e.g., a > 25% decrease vs ≥ 50% decrease)
[35,99,105]. Additional imaging techniques and analyses
for the assessment or predictors of antiangiogenic treat-
ment response that have been proposed for additional
investigation include FLAIR MRI, dynamic contrast-
enhanced MRI, diffusion-weighted MRI, pretreatment
apparent diffusion coefficient histogram analysis, and per-
fusion imaging or dynamic susceptibility contrast MRI
[60,105-109]. The breadth of these recommendations
further underscores the need for a standardized approach
of response assessment.
Summary and Conclusions
Despite advances in treatment, glioblastoma has no cure,
and patients with glioblastoma have poor long-term sur-
vival. Increased understanding of the tumorigenesis of
this disease at the molecular level has led to the identifi-
cation of VEGF and its related pathways as targets for
t h e r a p y .A sar e s u l t ,an u m b e ro fa n t i a n g i o g e n i ct h e r a -
pies have been or are currently being evaluated in
patients with glioblastoma, alone or in combination with
chemotherapy and/or radiotherapy. The most well-
established antiangiogenic therapy is bevacizumab; cur-
rent experience encompasses clinical data from more
than 1000 patients treated for glioblastoma. In May
2009, single-agent bevacizumab was approved by the
FDA for the treatment of patients with progressive glio-
blastoma following prior therapy on the basis of an
improvement in objective response rate. The BRAIN
study that supported this approval also showed a signifi-
cant improvement in 6-month PFS rate with bevacizu-
mab alone and in combination with irinotecan relative
to historical controls [31]. At present, the NCCN guide-
lines include a recommendation for bevacizumab either
with or without chemotherapy as a treatment option for
recurrent glioblastoma [4]. The safety and efficacy of
cilengitide with chemotherapy has not been reported in
the recurrent setting, but single-agent data suggest that
combinatorial trials are warranted.
Clinical studies have also demonstrated the feasibility
of combining bevacizumab or cilengitide plus radiation
with or without concomitant temozolomide for the
treatment of patients with newly diagnosed or recurrent
glioblastoma. Early data suggest the possibility of novel
regimens that improve tumor response without overlap-
ping toxicities, but these findings are preliminary. The
incorporation of antiangiogenic agents in frontline ther-
apy, therefore, cannot be recommended at present,
except in the context of a clinical trial.
Although the safety and efficacy of combining antian-
giogenic agents with chemotherapy has been documented
in the recurrent setting, the ideal chemotherapy partner
has yet to be identified by prospective, randomized trials.
The difficulty of comparing data across trials prohibits
any definitive conclusions, and the efficacy signals to date
do not provide a clear indication as to which chemother-
apy agents or treatment schedules are optimal. Moreover,
the scheduling, timing, and dosing of antiangiogenic
agents relative to chemotherapy also remains to be
defined, and should be a focus of future studies. As the
field progresses toward patient-specific approaches, gene
expression studies and other correlative analyses are
needed to assess the safety and efficacy of antiangiogenic
therapies on the basis of the molecular pathophysiology
of the disease. Data obtained from ongoing studies should
enable clinicians to further optimize treatment for both
newly diagnosed and recurrent glioblastoma (Additional
file 1, Table S1). Additional information can be found at
http://www.ro-journal.com. Alternate treatment strategies
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antiangiogenic agent with other targeted agents, such as
erlotinib, dasatinib, or cetuximab [110,111]. More
research is also needed to establish the most advanta-
geous sequencing for individual components of combina-
tion regimens containing antiangiogenic therapies.
Antiangiogenic agents are expected to play a significant
role in the treatment of glioblastoma in the future, and it
is hoped that the consideration of molecular profiling will
further improve target selection.
Additional material
Additional file 1: Proposed and ongoing phase II and III trials of
antiangiogenic agents in glioma. Table of proposed and ongoing
phase II and phase III trials of select antiangiogenic agents for the
treatment of recurrent and newly diagnosed glioma, with study details
including NCT numbers, disease setting, primary endpoints, and leading
study center.
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